The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial

Arthritis and Rheumatology

Volumn 69, Issue 10, 2017, Pages 1969-1977

  Winthrop, Kevin L ^a   Wouters, Ann G ^b   Choy, Ernest H ^c   Soma, Koshika ^b   Hodge, Jennifer A ^b   Nduaka, Chudy I ^b   Biswas, Pinaki ^b   Needle, Elie ^b   Passador, Sherry ^b   Mojcik, Christopher F ^b   Rigby, William F ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISONE; TOFACITINIB; VALACICLOVIR; VARICELLA ZOSTER VACCINE; VIRUS ANTIBODY; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BIOPSY; BODY MASS; BRONCHITIS; CELLULAR IMMUNITY; CHICKENPOX; CHOLANGITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRANULOMATOSIS; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SKIN REDNESS; T LYMPHOCYTE; VACCINATION; VACCINE IMMUNOGENICITY; VARICELLA ZOSTER VIRUS; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

AGED; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; T-LYMPHOCYTES;

EID: 85028927004     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40187     Document Type: Article

References (31)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
2. Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 2016;68:2328–37.
3. Smolen J, Genovese M, Takeuchi T, Hyslop D, Macias WL, Rooney TP, et al. Safety profile of baricitinib in patients with active RA: integrated analysis [abstract]. Ann Rheum Dis 2016;75:THU0166.
4. Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma 2015;56:2067–74.
5. Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T, et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. Int J Rheum Dis 2016;19:1216–25.
6. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.
7. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495–507.
8. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451–60.
9. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four–month phase III randomized radiographic study. Arthritis Rheum 2013;65:559–70.
10. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253–61.
11. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.
12. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837–52.
13. Wollenhaupt J, Silverfield J, Lee EB, Wood SP, Terry K, Nakamura H, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension over 6 years [abstract]. Ann Rheum Dis 2015;74:259.
14. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford) 2012;51 Suppl 6:vi37–43.
15. Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1843–7.
16. Winthrop KL, Curtis JR, Lindsey S, Valdez H, Fan H, Wang L, et al. Herpes zoster and tofacitinib: the risk of concomitant nonbiologic therapy [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/herpes-zoster-and-tofacitinib-the-risk-of-concomitant-nonbiologic-therapy.
17. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 2014;63:729–31.
18. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
19. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414–22.
20. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:309–18.
21. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.
22. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796–806.
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
24. Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, et al. Varicella-zoster virus-specific antibody responses in 50–59-year-old recipients of zoster vaccine. J Infect Dis 2013;208:1386–90.
25. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197:825–35.
26. Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol 2016;28:330–6.
27. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep 2014;16:431.
28. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84.
29. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012;54:922–8.
30. ® (Zoster vaccine live) suspension for subcutaneous injection, highlights of prescribing information. 2016. URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM132831.pdf.
31. Pierson DL, Mehta SK, Gilden D, Cohrs RJ, Nagel MA, Schmid DS, et al. Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization. J Infect Dis 2011;203:1542–5.